Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
p-Aminohippuric acid (PAH) is a synthetic derivative of hippuric acid formed by the conjugation of glycine and p-aminobenzoic acid. It is not naturally present in humans and must be administered intravenously for diagnostic use. PAH is primarily used as a diagnostic agent to measure effective renal plasma flow (ERPF) and assess the functional capacity of the renal tubular secretory mechanism. After administration, it is filtered by the glomeruli and actively secreted by proximal tubules in the kidney; at low plasma concentrations about 90% is cleared from renal blood in one circulation. Its high clearance rate makes it ideal for ERPF measurement. The compound itself has minimal toxicity at recommended doses[1][2][3][4][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on p-aminohippuric acid.